Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764633 · ClinicalTrials.gov registry record · Phase 3
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 27,564
- Enrollment target
NCT01764633 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 27,564 participants.
The verdict
NCT01764633, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27,564 participants
- Enrollment target
Study Summary
The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.
Interventions
- DRUG Placebo
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27,564 participants |
| Start Date | 2013-02-08 |
| Est. Completion | 2016-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764633
The ClinicalTrials.gov registry entry for NCT01764633 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27,564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01764633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01764633 about?
NCT01764633 is a clinical study titled "Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk". The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident c...
What is the current status of trial NCT01764633?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27,564 participants. The study started on 2013-02-08. Estimated completion is 2016-11-11.
What interventions are being tested in trial NCT01764633?
The interventions under investigation include: Placebo (DRUG), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01764633?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.